PRF-110
Post-operative pain following bunionectomy
Key Facts
About PainReform
PainReform's mission is to transform post-operative care by developing proprietary, extended-release formulations of established therapeutics to reduce opioid reliance. Its core achievement is the advancement of PRF-110 into Phase 3 for bunionectomy pain, with positive Phase 2 data in hernia repair. The company's strategy leverages a lower-risk reformulation approach to create new intellectual property and has recently expanded its scope to include AI for solar energy optimization under the new PRF Technologies umbrella.
View full company profileAbout PainReform
PainReform's mission is to transform post-operative care by developing proprietary, extended-release formulations of established therapeutics to reduce opioid reliance. Its core achievement is the advancement of PRF-110 into Phase 3 for bunionectomy pain, with positive Phase 2 data in hernia repair. The company's strategy leverages a lower-risk reformulation approach to create new intellectual property and has recently expanded its scope to include AI for solar energy optimization under the new PRF Technologies umbrella.
View full company profile